Cancer treatment does not replace chemotherapy or radiotherapy

The Ministry of Health on Thursday revealed the truth about a cancer drug, pointing out that it was not a substitute for surgical treatment, chemotherapy and radiation therapy.

"The drug Vitrakvi is the commercial name of Larotrectinib," said the ministry in a statement. "It does not treat cancer, nor does it fully recover from the original mentioned, but aims to control growth and spread as long as possible."

The New England Journal of Medicine published the study, which was in the first and second phase of Larotrectinib, involving 55 cancer patients with the TRK gene mutation. Confirming that the full response rate was 13% and the partial response rate was 62%.

The response did not last long in all patients: the disease developed in some of the participants, while the response continued in 39% of patients after the first year of treatment, and some patients have had postoperative surgery.

This new treatment has recently been approved by the Food and Drug Administration (FDA) to treat specific cases of cancer with a specific type of rare genetic mutations (TRK gene) present in certain tumors such as the salivary gland, the thyroid, the lung and connective tissue, as well as the treatment of genetic mutations Surgery is not tolerable, as are cases that contain the genetic mutation and there is no suitable alternative to treatment and cases developed after treatment.